首页> 外文期刊>Japanese heart journal >The Paradoxical Adverse Effect of Verapamil for Treating Clinical Paroxysmal Supraventricular Tachycardia
【24h】

The Paradoxical Adverse Effect of Verapamil for Treating Clinical Paroxysmal Supraventricular Tachycardia

机译:维拉帕米治疗临床阵发性室上性心动过速的悖论性不良反应

获取原文
获取外文期刊封面目录资料

摘要

The intravenous administration of verapamil to 2 patients with paroxysmal supraventricular tachycardia (PSVT) resulted in an induction of PSVT during a programmed electrophysiological stimulation study. Each patient had a documented episode of PSVT. Baseline programmed stimulation studies revealed neither induction of PSVT nor an atrial echo; however, PSVT was induced immediately after injecting verapamil (0.15mg/kg) intravenously in both patients. In 1 patient, the study was repeated 2 days later and similar results were obtained. The serum concentration of verapamil when PSVT was induced was about 80ng/ml in both cases. Clinicians using verapamil should note that this antiarrhythmic drug may aggravate PSVT, depending on critical changes in AV nodal conduction and refractoriness.
机译:在2例阵发性室上性心动过速(PSVT)病人中静脉给予维拉帕米,导致在程序性电生理刺激研究中诱发PSVT。每个患者都有记录的PSVT发作。基线程序性刺激研究未显示PSVT的诱发或心房回声。然而,两名患者均静脉注射维拉帕米(0.15mg / kg)后立即诱发PSVT。在1名患者中,该研究在2天后重复进行,并获得了相似的结果。在两种情况下,诱发PSVT时维拉帕米的血清浓度约为80ng / ml。使用维拉帕米的临床医生应注意,这种抗心律失常药物可能会加重PSVT,这取决于房室淋巴结传导和难治性的严重变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号